JCR Pharma, Apr-Jun (1Q) Net Income Turns to Loss

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Jul 30, 2025 4:00 pm JST Earnings

4552 JCR Pharmaceuticals Co.,Ltd. 【J-GAAP】

Earnings Report

JCR Pharmaceuticals Co.,Ltd. <4552> [TSE Prime] announced its financial results after the market closed on July 30th (16:00). The consolidated net income/loss for the first quarter of the fiscal year ending March 2026 (April to June) turned into a loss of 546 million yen (compared to a profit of 201 million yen in the same period last year).

In the most recent three-month period, from April to June (1Q), the operating profit/loss margin drastically worsened from -3.6% in the same period last year to -7.1%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	10,808	2,066	2,260	1,610	12.9	31.7	Jul 26, 2023	J-GAAP
Apr - Jun, 2024	8,145	-296	-257	201	1.6	ー	Jul 30, 2024	J-GAAP
Apr - Jun, 2025	8,569	-606	-749	-546	-4.5	ー	Jul 30, 2025	J-GAAP
YoY	+5.2%	-104.7%	-191.4%	－	－

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	16,657	-739	-1,621	-691	-5.5	10	Oct 30, 2024	J-GAAP
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	10	May 13, 2025	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	42,871	7,531	7,264	5,507	44.1	20	May 10, 2024	J-GAAP
Mar, 2025	33,072	-6,650	-7,477	-4,759	-38.4	20	May 13, 2025	J-GAAP
Mar, 2026 Guidance	37,800	2,600	2,400	3,000	24.6	20	May 13, 2025	J-GAAP
YoY	+14.3%	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	8,145	-296	-257	201	1.6	-3.6	Jul 30, 2024	J-GAAP
Jul - Sep, 2024	8,512	-443	-1,364	-892	-7.1	-5.2	Oct 30, 2024	J-GAAP
Oct - Dec, 2024	9,223	-15	241	115	0.9	-0.2	Jan 31, 2025	J-GAAP
Jan - Mar, 2025	7,192	-5,896	-6,097	-4,183	-33.8	-82.0	May 13, 2025	J-GAAP
Apr - Jun, 2025	8,569	-606	-749	-546	-4.5	-7.1	Jul 30, 2025	J-GAAP
YoY	+5.2%	-104.7%	-191.4%	－	－